Hormonal therapy in uterine sarcomas
Abstract Uterine sarcomas (USs) are a group of rare but aggressive uterine malignancies, accounting for only 1% of the malignant tumors of female reproductive organs. Due to the high rate of recurrence and metastasis, the prognosis of USs is poor. Given the high mortality rate and limited clinical b...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-04-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2044 |
| _version_ | 1827580527724462080 |
|---|---|
| author | Yuqin Zang Mengting Dong Kai Zhang Chao Gao Fei Guo Yingmei Wang Fengxia Xue |
| author_facet | Yuqin Zang Mengting Dong Kai Zhang Chao Gao Fei Guo Yingmei Wang Fengxia Xue |
| author_sort | Yuqin Zang |
| collection | DOAJ |
| description | Abstract Uterine sarcomas (USs) are a group of rare but aggressive uterine malignancies, accounting for only 1% of the malignant tumors of female reproductive organs. Due to the high rate of recurrence and metastasis, the prognosis of USs is poor. Given the high mortality rate and limited clinical benefit of surgery and adjuvant chemoradiotherapy, hormonal therapy has shown good prospects in recent years. Hormonal agents include progestins, aromatase inhibitors (AIs), and gonadotropin‐releasing hormone analogue (GnRH‐a). According to the literature, hormonal therapy has been confirmed effective for recurrent, metastatic or unresectable low‐grade endometrial stromal sarcoma (LGESS) and hormone receptor positive (ER+/PR+) uterine leiomyosarcoma (uLMS) with favorable tolerance and compliance. Besides, hormonal therapy can also be used in patients with early‐staged disease who desire to preserve fertility. However, due to the rarity of USs, the rationale of hormonal therapy is generally extrapolated from data of hormone‐sensitive breast cancer, and present studies of hormonal therapy in USs were almost limited to case reports and small‐sized retrospective studies. Therefore, further systematic researches and standardized clinical trials are needed to establish the optimal hormonal therapy regimen of USs. Herein, we reviewed the existing studies related to the hormonal therapy in USs in order to provide reference for clinical management in specific settings. |
| first_indexed | 2024-03-08T22:20:23Z |
| format | Article |
| id | doaj.art-82785e846f404377824475b1acf3f1f4 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-03-08T22:20:23Z |
| publishDate | 2019-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-82785e846f404377824475b1acf3f1f42023-12-18T12:55:50ZengWileyCancer Medicine2045-76342019-04-01841339134910.1002/cam4.2044Hormonal therapy in uterine sarcomasYuqin Zang0Mengting Dong1Kai Zhang2Chao Gao3Fei Guo4Yingmei Wang5Fengxia Xue6Department of Gynecology and Obstetrics Tianjin Medical University General Hospital Tianjin ChinaDepartment of Gynecology and Obstetrics Tianjin Medical University General Hospital Tianjin ChinaDepartment of Gynecology and Obstetrics Tianjin Medical University General Hospital Tianjin ChinaDepartment of Gynecology and Obstetrics Tianjin Medical University General Hospital Tianjin ChinaDepartment of Gynecology and Obstetrics Tianjin Medical University General Hospital Tianjin ChinaDepartment of Gynecology and Obstetrics Tianjin Medical University General Hospital Tianjin ChinaDepartment of Gynecology and Obstetrics Tianjin Medical University General Hospital Tianjin ChinaAbstract Uterine sarcomas (USs) are a group of rare but aggressive uterine malignancies, accounting for only 1% of the malignant tumors of female reproductive organs. Due to the high rate of recurrence and metastasis, the prognosis of USs is poor. Given the high mortality rate and limited clinical benefit of surgery and adjuvant chemoradiotherapy, hormonal therapy has shown good prospects in recent years. Hormonal agents include progestins, aromatase inhibitors (AIs), and gonadotropin‐releasing hormone analogue (GnRH‐a). According to the literature, hormonal therapy has been confirmed effective for recurrent, metastatic or unresectable low‐grade endometrial stromal sarcoma (LGESS) and hormone receptor positive (ER+/PR+) uterine leiomyosarcoma (uLMS) with favorable tolerance and compliance. Besides, hormonal therapy can also be used in patients with early‐staged disease who desire to preserve fertility. However, due to the rarity of USs, the rationale of hormonal therapy is generally extrapolated from data of hormone‐sensitive breast cancer, and present studies of hormonal therapy in USs were almost limited to case reports and small‐sized retrospective studies. Therefore, further systematic researches and standardized clinical trials are needed to establish the optimal hormonal therapy regimen of USs. Herein, we reviewed the existing studies related to the hormonal therapy in USs in order to provide reference for clinical management in specific settings.https://doi.org/10.1002/cam4.2044aromatase inhibitorsgonadotropin‐releasing hormone analoguehormonal therapyprogestinsuterine sarcomas |
| spellingShingle | Yuqin Zang Mengting Dong Kai Zhang Chao Gao Fei Guo Yingmei Wang Fengxia Xue Hormonal therapy in uterine sarcomas Cancer Medicine aromatase inhibitors gonadotropin‐releasing hormone analogue hormonal therapy progestins uterine sarcomas |
| title | Hormonal therapy in uterine sarcomas |
| title_full | Hormonal therapy in uterine sarcomas |
| title_fullStr | Hormonal therapy in uterine sarcomas |
| title_full_unstemmed | Hormonal therapy in uterine sarcomas |
| title_short | Hormonal therapy in uterine sarcomas |
| title_sort | hormonal therapy in uterine sarcomas |
| topic | aromatase inhibitors gonadotropin‐releasing hormone analogue hormonal therapy progestins uterine sarcomas |
| url | https://doi.org/10.1002/cam4.2044 |
| work_keys_str_mv | AT yuqinzang hormonaltherapyinuterinesarcomas AT mengtingdong hormonaltherapyinuterinesarcomas AT kaizhang hormonaltherapyinuterinesarcomas AT chaogao hormonaltherapyinuterinesarcomas AT feiguo hormonaltherapyinuterinesarcomas AT yingmeiwang hormonaltherapyinuterinesarcomas AT fengxiaxue hormonaltherapyinuterinesarcomas |